Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Room 619, LKSKI, 30 Bond Street, Toronto, ON, M5B1W8, Canada.
Department of Internal Medicine D, Rambam Health Care Campus, Haifa, Israel.
Crit Care. 2021 Jul 12;25(1):244. doi: 10.1186/s13054-021-03662-x.
The major variant of concerns (VOCs) have shared mutations in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins, mostly on the S1 unit and resulted in higher transmissibility rate and affect viral virulence and clinical outcome. The spike protein mutations and other non-structural protein mutations in the VOCs may lead to escape approved vaccinations in certain extend. We will discuss these VOC mutations and discuss the need for combination therapeutic strategies targeting viral cycle and immune host responses.
主要关切的变异株（VOCs）在严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突蛋白上具有共享突变，主要在 S1 单位，导致更高的传染性，并影响病毒毒力和临床结果。VOCs 中的刺突蛋白突变和其他非结构蛋白突变可能在一定程度上导致已批准疫苗的逃逸。我们将讨论这些 VOC 突变，并讨论针对病毒周期和宿主免疫反应的联合治疗策略的必要性。
